Elranatamab,lenalidomide,daratumumab,PF-06863135,tocilizumab
pfizer,janssen,roche
['toci', 'magnetismm-5', 'mmsm', 'cll', 'nct05020236', 'fil,veral,12', 'elranatamab', '2019', '1921', 'tocilizumab', 'emergent ', 'effector ', 'imab ']
elranatamab phase 2: 61% orr and 84% 9-month dor in triple-class penta-drug refractory myeloma. no grade 3 crs or icans, 67% infection aes #ash22 #mmsm 
MD PhD, Specialized in Multiple Myeloma. Memorial Sloan Kettering Cancer Center. Karolinska Institute. Tweets are my own.